Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

Progressive disability in multiple sclerosis occurs because CNS axons degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma agonists promote remyelination. We aimed to assess the safety and efficacy of a non-selective retinoid X receptor agonist in promoting...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology Jg. 20; H. 9; S. 709 - 720
Hauptverfasser:	Brown, J William L, Cunniffe, Nick G, Prados, Ferran, Kanber, Baris, Jones, Joanne L, Needham, Edward, Georgieva, Zoya, Rog, David, Pearson, Owen R, Overell, James, MacManus, David, Samson, Rebecca S, Stutters, Jonathan, ffrench-Constant, Charles, Gandini Wheeler-Kingshott, Claudia A M, Moran, Carla, Flynn, Paul D, Michell, Andrew W, Franklin, Robin J M, Chandran, Siddharthan, Altmann, Daniel R, Chard, Declan T, Connick, Peter, Coles, Alasdair J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.09.2021 Elsevier Limited
Schlagworte:	Acids Adult Adverse events Agonists Axons Bexarotene - administration & dosage Bexarotene - adverse effects Bexarotene - pharmacology Cholecystitis Clinical trials Demyelination Disability Double-Blind Method Double-blind studies Drug-Related Side Effects and Adverse Reactions Evoked Potentials, Visual - physiology Female Humans Hypothyroidism Licenses Magnetic Resonance Imaging Male Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - physiopathology Myelination Neutropenia Outcome Assessment, Health Care Patients Placebos Remyelination - drug effects Retinoid X receptors Retinoid X Receptors - agonists Safety Statistical analysis United Kingdom > UK
ISSN:	1474-4422, 1474-4465, 1474-4465
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!